[go: up one dir, main page]

DK3512833T3 - Heteroarylcarboxamidforbindelser som inhibitorer af ripk2 - Google Patents

Heteroarylcarboxamidforbindelser som inhibitorer af ripk2 Download PDF

Info

Publication number
DK3512833T3
DK3512833T3 DK17768914.8T DK17768914T DK3512833T3 DK 3512833 T3 DK3512833 T3 DK 3512833T3 DK 17768914 T DK17768914 T DK 17768914T DK 3512833 T3 DK3512833 T3 DK 3512833T3
Authority
DK
Denmark
Prior art keywords
ripk2
inhibitors
carboxamide compounds
heteroaryl carboxamide
heteroaryl
Prior art date
Application number
DK17768914.8T
Other languages
English (en)
Inventor
Maolin Yu
Pingrong Liu
Craig Andrew Miller
Zhonghua Zhang
Sabine Ruppel
Anil K Padyana
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK3512833T3 publication Critical patent/DK3512833T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
DK17768914.8T 2016-09-15 2017-09-06 Heteroarylcarboxamidforbindelser som inhibitorer af ripk2 DK3512833T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662394779P 2016-09-15 2016-09-15
PCT/US2017/050197 WO2018052772A1 (en) 2016-09-15 2017-09-06 Heteroaryl carboxamide compounds as inhibitors of ripk2

Publications (1)

Publication Number Publication Date
DK3512833T3 true DK3512833T3 (da) 2020-10-12

Family

ID=59901598

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17768914.8T DK3512833T3 (da) 2016-09-15 2017-09-06 Heteroarylcarboxamidforbindelser som inhibitorer af ripk2

Country Status (32)

Country Link
US (4) US10138241B2 (da)
EP (1) EP3512833B1 (da)
JP (1) JP6733050B2 (da)
KR (1) KR102472736B1 (da)
CN (1) CN110023290B (da)
AR (1) AR109650A1 (da)
AU (1) AU2017327539B2 (da)
BR (1) BR112019003320B1 (da)
CA (1) CA3037141A1 (da)
CL (1) CL2019000476A1 (da)
CO (1) CO2019001181A2 (da)
CY (1) CY1123494T1 (da)
DK (1) DK3512833T3 (da)
EA (1) EA038128B1 (da)
ES (1) ES2816003T3 (da)
HR (1) HRP20201494T1 (da)
HU (1) HUE051551T2 (da)
IL (1) IL265062B (da)
LT (1) LT3512833T (da)
MA (1) MA46229B1 (da)
MX (1) MX387443B (da)
NZ (1) NZ750416A (da)
PE (1) PE20190979A1 (da)
PH (1) PH12019500497A1 (da)
PL (1) PL3512833T3 (da)
PT (1) PT3512833T (da)
RS (1) RS60729B1 (da)
SA (1) SA519401322B1 (da)
SI (1) SI3512833T1 (da)
TW (1) TWI749062B (da)
UA (1) UA123287C2 (da)
WO (1) WO2018052772A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3464336T3 (pl) 2016-06-01 2022-05-16 Athira Pharma, Inc. Związki
US10138222B2 (en) 2016-09-15 2018-11-27 Boehringer Ingelheim International Gmbh Substituted benzamides as RIPK2 inhibitors
NZ750416A (en) 2016-09-15 2022-04-29 Boehringer Ingelheim Int Heteroaryl carboxamide compounds as inhibitors of ripk2
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN113874015B (zh) * 2018-12-21 2024-05-24 细胞基因公司 Ripk2的噻吩并吡啶抑制剂
WO2020198053A1 (en) * 2019-03-22 2020-10-01 Takeda Pharmaceutical Company Limited 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases
JP2025519537A (ja) 2022-06-10 2025-06-26 インターライン セラピューティクス インコーポレイテッド Ｒｉｐｋ２阻害剤としてのイミダゾ（１，２－１）ピリジン誘導体
WO2024254539A1 (en) 2023-06-09 2024-12-12 Interline Therapeutics, Inc. Methods of treating inflammatory diseases
WO2024259328A1 (en) * 2023-06-16 2024-12-19 Odyssey Therapeutics, Inc. Inhibitors of ripk2 and uses thereof
WO2025085928A1 (en) 2023-10-20 2025-04-24 Odyssey Therapeutics, Inc. Methods of treating a patient with an inflammatory bowel disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2438991C (en) 2001-02-21 2010-08-17 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2004099156A1 (en) 2003-05-01 2004-11-18 Bristol-Myers Squibb Company Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
UA95298C2 (ru) 2006-07-07 2011-07-25 Бьёрингер Ингельхайм Интернациональ Гмбх Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств
KR101165936B1 (ko) 2006-11-09 2012-07-19 에프. 호프만-라 로슈 아게 티아졸 및 옥사졸-치환된 아릴아마이드
US20110009437A1 (en) 2008-02-27 2011-01-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Carboxamide-heteroaryl derivatives for the treatment of diabetes
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
EP2552211A4 (en) 2010-03-26 2013-10-23 Glaxo Group Ltd INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
JP2013523766A (ja) * 2010-03-31 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのイミダゾリル‐イミダゾール
UY33808A (es) 2010-12-17 2012-07-31 Syngenta Participations Ag Compuestos insecticidas
CA2826059A1 (en) 2011-02-09 2012-08-16 Pierre Joseph Marcel Jung Insecticidal compounds
AR091490A1 (es) 2012-06-19 2015-02-11 Bristol Myers Squibb Co Antagonistas de iap
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
US20140142129A1 (en) 2012-11-20 2014-05-22 Celgene Avilomics Research, Inc, Methods of treating a disease or disorder associated with bruton's tyrosine kinase
PT2953942T (pt) * 2013-02-06 2018-01-17 Bayer Cropscience Ag Derivados de pirazol substituídos com halogéneo como agentes pesticidas
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
ES2683693T3 (es) 2014-01-03 2018-09-27 Bayer Animal Health Gmbh Nuevas pirazolil-heteroarilamidas como agentes plaguicidas
CA2964282C (en) * 2014-10-27 2023-03-07 University Health Network Ripk2 inhibitors and method of treating cancer with same
FI3504187T3 (fi) 2016-08-24 2025-04-05 Prilenia Neurotherapeutics Ltd Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
NZ750416A (en) 2016-09-15 2022-04-29 Boehringer Ingelheim Int Heteroaryl carboxamide compounds as inhibitors of ripk2
US10138222B2 (en) 2016-09-15 2018-11-27 Boehringer Ingelheim International Gmbh Substituted benzamides as RIPK2 inhibitors

Also Published As

Publication number Publication date
WO2018052772A1 (en) 2018-03-22
CN110023290A (zh) 2019-07-16
US11130754B2 (en) 2021-09-28
EP3512833B1 (en) 2020-07-29
US12139484B2 (en) 2024-11-12
US20190048000A1 (en) 2019-02-14
JP2019529407A (ja) 2019-10-17
US20180072717A1 (en) 2018-03-15
JP6733050B2 (ja) 2020-07-29
BR112019003320A2 (pt) 2019-06-04
KR102472736B1 (ko) 2022-12-02
RS60729B1 (sr) 2020-09-30
NZ750416A (en) 2022-04-29
US20220081437A1 (en) 2022-03-17
EP3512833A1 (en) 2019-07-24
TW201823227A (zh) 2018-07-01
AU2017327539A1 (en) 2019-02-21
HUE051551T2 (hu) 2021-03-01
PE20190979A1 (es) 2019-07-09
LT3512833T (lt) 2020-10-12
EA201990678A1 (ru) 2019-09-30
CA3037141A1 (en) 2018-03-22
US20250042901A1 (en) 2025-02-06
AU2017327539B2 (en) 2020-12-24
PL3512833T3 (pl) 2021-01-11
MX387443B (es) 2025-03-18
SI3512833T1 (sl) 2020-11-30
PH12019500497A1 (en) 2019-12-11
IL265062B (en) 2021-04-29
HRP20201494T1 (hr) 2020-12-11
ES2816003T3 (es) 2021-03-31
UA123287C2 (uk) 2021-03-10
MA46229B1 (fr) 2020-10-28
CO2019001181A2 (es) 2019-02-19
CL2019000476A1 (es) 2019-05-31
CY1123494T1 (el) 2022-03-24
US10138241B2 (en) 2018-11-27
SA519401322B1 (ar) 2022-05-10
TWI749062B (zh) 2021-12-11
MA46229A (fr) 2019-07-24
KR20190047046A (ko) 2019-05-07
EA038128B1 (ru) 2021-07-09
PT3512833T (pt) 2020-09-24
BR112019003320B1 (pt) 2024-02-20
CN110023290B (zh) 2022-08-12
AR109650A1 (es) 2019-01-09
MX2019003026A (es) 2019-07-01

Similar Documents

Publication Publication Date Title
DK3512833T3 (da) Heteroarylcarboxamidforbindelser som inhibitorer af ripk2
IL263586B (en) Inhibitors of the menin-mll interaction
DK3164130T3 (da) Heteroaryle forbindelser anvendelige som inhibatorer af sumo-aktiverende enzym
DK3377059T3 (da) Hæmmere af cxcr2
DK3442947T3 (da) Aminsubstituerede aryl- eller heteroarylforbindelser som ehmt1- og ehmt2-hæmmere
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3371171T3 (da) Inhibitorer af RET
DK3529241T3 (da) Pireridinderivater som inhibitorer af ubiquitin-specifik protease 7
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3356345T3 (da) Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3377488T3 (da) Heterocykliske forbindelser som immunomodulatorer
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3473621T3 (da) Fremgangsmåde til fremstilling af diphenylmethan-derivat
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3368683T3 (da) Fremgangsmåde til kvantifikationen af pd-l1
DK3348556T3 (da) Heteroarylamider som hæmmere af proteinaggregering
DK3551625T3 (da) Heterocykliske inhibitorer af mct4
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3157929T3 (da) Pyrazolforbindelser som modulatorer af fshr og anvendelser deraf
DK3313833T3 (da) Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase
DK3457851T3 (da) Derivater af sobetirom
DK3692039T3 (da) Enantiomerer af substituerede thiazoler som antivirale forbindelser
DK3204352T3 (da) Hæmmere af lysin-gingipain